Article
EULAR 2023 launched today to crowds of attendees. The opening Plenary session and presidential address by Dr.
All News
Article
In the last 2 years, there has been more caution and vigilance with the use of JAK inhibitors in the treatment of rheumatoid arthritis due to the risk of CV events, including MACE and VTE. The ORAL surveillance study, a post-approval safety study conducted in RA patients aged ≥50 years with ≥1 CV risk factor, has resulted in increased caution and greater emphasis on assessment of MACE and VTE risks in patients starting JAK inhibitors.
Article
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR
Article
Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling.
Article
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
Article
Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease: Improving
David Liew
Tweet
Do we use too much PNL in GCA (when not using TCZ)? Could we wean quicker?
Salvarini group n=22
26w PNL weaning protocol from GiACTA, but no TCZ
10/26 in relapse free remission at 1y
Much less PNL, still some steroid AEs
Way of the future for some?
POS0728 #EULAR2023 @RheumNow https://t.co/qeZHeCi9vq
Janet Pope
Tweet
You need to see this! Albert with a Left V1 distribution of #shingles is a ‘bot’ who interacts with #rheumatologists at #EULAR2023 @RheumNow @eular_org #artificial #intelligence https://t.co/gDwzc3NX7v
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 #POS0627 Researchers in Manchester identified several proteins associated with subclinical cardiovascular abnormalities on Cardiac MRI in Scleroderma using proteomics. Need validation. Could be useful for stratification and identify therapeutic targets @RheumNow https://t.co/55eNGhMu5f
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 #POS0618 This is cool! Researchers from Switzerland are developing new Quantitative Radiomic Risk Score (from HRCT) to stratify response to Anti-Fibrotic in #ILD. Data presented in pre-clinical study & paralleled molecular effects. Human study is in progress @RheumNow https://t.co/qAsWew4FEO
Aurelie Najm
Tweet
Are we going to treat hands OA with MTX?
Moderate effect on VAS pain at 6 and 12 months in a small RCT vs. PBO in hands OA WITH MRI detected synovitis.
Thoughts
1) Is it really OA?
2) Benefit Risk balance remains debatable
@RheumNow OP0070 #EULAR23 https://t.co/WLlX48NtGT
Bella Mehta
Tweet
#CPPD and #cervical involvement. Several clinical presentations
A-asymptomatic deposition
B-crowned dens syndrome
C-retro-odontoid pseudotumor
D-inflammatory discitis
Good teaching points in the supplements! @RheumNow #EULAR2023 Abst#AB1859 https://t.co/LJe7Gk1oZX
Md Yuzaiful Md Yusof
Tweet
#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed:
- 1 in 10 people had AID in the last 20yrs
- socioeconomic, seasonal & regional disparities cd influence pathogenesis
- CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC
Bella Mehta
Tweet
Colchicine 0.5mg BID for 12 weeks in #HandOA did not relieve pain. Results from 186 pts- double blind placebo controlled, randomized. MCID on VAS of 15 was not achieved. Presented at #EULAR2023 today abst#op0073
@RheumNow
Aurelie Najm
Tweet
EULAR PtoC management of targeted therapies in pts w/ IA & Hx cancer
1) If remission, initiate targeted therapy w/out delay
2) Prefer anti-cytokine bDMARDs if Hx solid cancer
3) B cell depleting therapy if Hx lymphoma
4) Use JAK inhibitors and abatacept with caution 🛑 https://t.co/cKhQVZwGh1
Dr. Antoni Chan
Tweet
Nathalie Conrad, Abstr#OP0007 @RheumNow presenting on the incidence, prevalence and co-occurrence of autoimmune disease - no evidence of overall increase in conditions. Environmental and socioeconomic factors involved in the presentation of the conditions https://t.co/3jy9NoltkG
David Liew
Tweet
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
David Liew
Tweet
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later?
Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses
SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
Janet Pope
Tweet
Researchers@of tomorrow. Winners of EULAR basic and epi and clinical abstract awards - young leaders! @RheumNow #EULAR2023 @eular_org https://t.co/VsV5aQpxjs
Dr. John Cush
Tweet
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for:
-KOL perspective videos
-Clinical Trial Highlights
-Daily Faculty Recaps
-Live Streaming
and more! https://t.co/9uKnDTynfk
